Excipients

Excipient Compliance & Audit Services

Helping excipient manufacturers establish GMP/GDP systems, prepare for EXCiPACT and USP Verification, and compile Excipient DMF dossiers.

  • Market route first
  • Evidence files aligned
  • Less rework before audits
Core Challenges

Excipient Supply Chain Compliance Challenges

As global drug supply chain controls tighten, excipient suppliers face heavy audit burdens from pharma buyers and industry certifications.

Heavy Pharma Audit Burden

Excipient plants face frequent, redundant audits from dozens of pharmaceutical buyers.

EXCiPACT & USP Verification

Overseas buyers often request third-party EXCiPACT certification or USP Excipient Verification.

Pharmacopoeia Conformity

Products must strictly conform to monograph specs in USP-NF, EP, BP, and other pharmacopoeias.

GDP/GWP Storage Controls

Preventing contamination and mix-ups, and securing temperature/humidity traceability in storage.

Solutions

Related Compliance Support

QTC uses EXCiPACT, USP, and buyer supplier-quality requirements to help excipient sites organize system evidence, site risks, and audit readiness priorities.

EXCiPACT / USP Verification Readiness Consulting

8-14 weeks

For: Excipient manufacturers or distributors seeking third-party certification to minimize customer audits.

Key Goal

Goal: Upgrade the QMS to pass on-site certification audits and secure certificates

What you get
  • Gap report aligned with EXCiPACT (GMP/GDP) / USP <1078> / ANSI 363
  • Remediation plans for material handling, traceability, and cross-contamination (cleanliness validation)
  • Coaching for upgrading laboratory controls, change control, and deviation management
  • Mock audit exercise and nonconformity remediation closure support

Excipient Drug Master File (DMF) Filing Support

6-10 weeks

For: Manufacturers submitting an Excipient DMF (Type IV) to the FDA or registering with China’s NMPA.

Key Goal

Goal: Submit and activate the DMF to allow downstream drug manufacturers to reference your excipient

What you get
  • Evaluation report on excipient manufacturing process, characterization, impurities, and specifications
  • Compilation of Excipient Drug Master File (DMF) meeting FDA or NMPA dossier requirements
  • Facilitate FDA submission to obtain a DMF number and Letter of Authorization (LOA)
  • Coaching for responding to regulatory deficiency letters

Excipient Supplier Qualification & Second-Party Audit Coaching

4-8 weeks

For: Pharma buyers commissioning QTC for excipient supplier on-site audits, or excipient sites improving second-party audit readiness.

Key Goal

Goal: Establish a quantifiable excipient supplier quality tiering system, reducing uninspected batches and non-conformance risk

What you get
  • Second-party audit report for major excipient suppliers aligned with ICH Q9 risk principles
  • Quality Agreement drafting and review support
  • CoA, sizing validation, and stability report review for supplier-submitted data
  • Quality scorecard design and guidance on supplier nonconformity closure

Excipient Elemental Impurity (ICH Q3D) & Residual Solvent Risk Assessment Coordination

3-6 weeks

For: Excipient sites requiring ICH Q3D elemental PDE limit assessments, residual solvent risk classification, or analytical method validation.

Key Goal

Goal: Complete impurity control data to support customer verification projects or DMF regulatory review

What you get
  • Excipient elemental impurity risk assessment report (covering Class 1/2A/2B/3 list)
  • ICP-MS/ICP-OES test plan design and ISO 17025 lab arrangement
  • ICH Q3C Class I/II residual solvent classification and monitoring plan
  • Analytical validation documentation drafting (to be merged into DMF or submitted independently)
Regulatory References

Global Excipient Standards

These standards guide international pharmaceutical companies in qualifying raw material suppliers.

EXCiPACT

Globally recognized third-party GMP/GDP certification standard for excipients.

USP Excipient Verification

USP’s official verification program, including site audits, dossier review, and lab testing.

USP <1078> / ANSI 363

Joint excipient GMP guidelines adopted by USP, forming the QMS baseline.

EU 2015/C 95/02

EU guidelines mandating formal risk assessments to define the appropriate excipient GMP level.

FAQ

Frequently Asked Questions

Answering quality system and certification queries for excipient manufacturers.

Sustainability & ESG

Do Your Buyers Also Request ESG Evidence?

Pharma brands and manufacturers increasingly face social audits (EcoVadis, CDP, carbon footprints, human rights) alongside standard GxP/cGMP quality requirements.

Need EXCiPACT Gap Assessment or Excipient DMF Submission?

Provide excipient details, synthesis/process type, target market, and QA framework. QTC experts will design a certification/filing plan.

Contact QTC